OncLive TV

Terri Parker, MD, discusses considerations to optimize treatment in multiple myeloma.

Gretchen G. Kimmick, MD, MS, discusses the results of the phase 2 ATEMPT trial in early-stage HER2-positive breast cancer

Deborah M. Stephens, DO, director of the CLL and Lymphoma Program, Huntsman Cancer Institute, discusses optimizing treatment selection in chronic lymphocytic leukemia.

Sarbajit Mukherjee, MD, MS, discusses considerations to inform when to initiate immunotherapy in gastroesophageal cancer.

Sarah Sammons, MD, discusses the clinical implications of the phase 3 DESTINY-Breast03 trial in HER2-positive breast cancer.

John L. Marshall, MD, discusses the potential utility of trastuzumab deruxtecan in HER2-positive gastric cancer.

Anthony Mato, MD, MSCE, discusses the potential utilization of CAR T-cell therapy in earlier lines of therapy in chronic lymphocytic leukemia.

Francisco Javier Esteva, MD, PhD, discusses the clinical implications of the fixed-dose regimen comprised of subcutaneous trastuzumab and pertuzumab in the treatment of patients with HER2-positive breast cancer.

Bilal A. Siddiqui, MD, discusses the potential for novel imaging in patients with nonmetastatic castration-resistant prostate cancer.

Ashish Saxena, MD, PhD, discusses a challenging case of a patient with non–small cell lung cancer.

Marjorie G. Zauderer, MD, discusses the importance of optimizing care for patients with mesothelioma.

Julie Renee Brahmer, MD, MSc, discusses questions regarding the role of consolidative immunotherapy vs targeted therapy in locally advanced non–small cell lung cancer.

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses the next steps to improve outcomes for patients with lung cancer.

Nathaniel Ivanick, MD, FCCP, discusses advancements in interventional pulmonology.

Nagashree Seetharamu, MD, MBBS, discusses the importance of utilizing a patient-centered treatment approach in lung cancer.

Marjorie G. Zauderer, MD, discusses emerging treatment strategies in mesothelioma.

Lori J. Wirth, MD, discusses the phase 3 LIBRETTO-531 trial of selpercatinib in patients with RET-mutant medullary thyroid cancer. 

Patrick Boland, MD, discusses the utility of circulating tumor DNA in patients with metastatic colorectal cancer.

Nancy E. Davidson, MD, shares how to leverage imaging technologies to inform treatment decisions in patients with breast cancer.

Glenn J. Hanna, MD, discusses the role of second-line cetuximab (Erbitux) in head and neck cancer.

Anthony Mato, MD, MSCE, discusses recent advances made in the treatment of patients with chronic lymphocytic leukemia.

Ajai Chari, MD, discusses recommendations for minimal residual disease testing in patients with multiple myeloma.

Francine Foss, MD, discusses pursing new therapeutic options for the treatment of patients with T-cell non-Hodgkin lymphoma.

Maher Albitar, MD, discusses the importance of obtaining genomic testing in oncology.

Marina Kremyanskaya, MD, PhD, discusses the need for disease-modifying treatment approaches for patients with myeloproliferative neoplasms.

Andrew T. Kuykendall, MD, discusses the potential for momelotinib in the treatment of patients with myelofibrosis.

Francisco Javier Esteva, MD, PhD, discusses therapeutic developments for patients with HER2-positive breast cancer.

Paul Lawrence Baron, MD, discusses contributing factors for developing breast cancer.

Jubilee Brown, MD, discusses the promise of the phase 2/3 ROCSAN trial in recurrent gynecologic carcinosarcomas.

Phillip Palmbos, MD, PhD, discusses updates and therapeutic recommendations for the frontline treatment of patients with bladder cancer.